5% sales growth for Johnson and Johnson's professional products sector
This article was originally published in Clinica
Sales growth in Johnson & Johnson's professional products division continued to be led by demand for Ethicon Endo-Surgery's minimally-invasive surgical instruments and LifeScan's blood glucose monitoring systems. Total 1997 sales in the division were $8.4 billion, up 5% on the previous year. Excluding exchange rate effects, the sector's growth would have been over 8%.
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.